These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8748393)

  • 21. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.
    Berg KA; Maayani S; Goldfarb J; Scaramellini C; Leff P; Clarke WP
    Mol Pharmacol; 1998 Jul; 54(1):94-104. PubMed ID: 9658194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In-vivo assessment of 5-HT2A and 5-HT2C antagonistic properties of newer antipsychotics.
    Sánchez C; Arnt J
    Behav Pharmacol; 2000 Jun; 11(3-4):291-8. PubMed ID: 11103883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The quipazine- and TFMPP-increased conditioned avoidance response in rats: role of 5HT1C/5-HT2 receptors.
    Alhaider AA; Ageel AM; Ginawi OT
    Neuropharmacology; 1993 Dec; 32(12):1427-32. PubMed ID: 8152532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the discriminative stimulus properties induced by 5-HT1 and 5-HT2 agonists in rats.
    Arnt J
    Pharmacol Toxicol; 1989 Feb; 64(2):165-72. PubMed ID: 2526950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropharmacological reassessment of the discriminative stimulus properties of d-lysergic acid diethylamide (LSD).
    Cunningham KA; Appel JB
    Psychopharmacology (Berl); 1987; 91(1):67-73. PubMed ID: 3103161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys: antagonism and apparent pA2 analyses.
    Li JX; Rice KC; France CP
    J Pharmacol Exp Ther; 2009 Mar; 328(3):976-81. PubMed ID: 19098164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
    Pierce PA; Peroutka SJ
    J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis.
    Dekeyne A; Girardon S; Millan MJ
    Neuropharmacology; 1999 Mar; 38(3):415-23. PubMed ID: 10219979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurochemical and behavioral evidence that quipazine-ketanserin discrimination is mediated by serotonin2A receptor.
    Smith RL; Barrett RJ; Sanders-Bush E
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1050-7. PubMed ID: 7473132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of serotonin 5-HT2C receptors in the rat choroid plexus after acute clozapine treatment.
    Kuoppamäki M; Seppälä T; Syvälahti E; Hietala J
    Eur J Pharmacol; 1994 Oct; 269(2):201-8. PubMed ID: 7851496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of 5-HT1B, 5-HT2A and 5-HT2C receptors in the generalization of 5-HT receptor agonists to the ethanol cue in the rat.
    Maurel S; Schreiber R; De Vry J
    Behav Pharmacol; 1998 Jul; 9(4):337-43. PubMed ID: 10065922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists.
    Glennon RA; Young R; Rosecrans JA
    Eur J Pharmacol; 1983 Jul; 91(2-3):189-96. PubMed ID: 6617740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-HT1C receptors mediate phosphoinositide turnover activation in the immature rat hippocampus.
    Claustre Y; Eudeline B; Benavides J; Scatton B
    Eur J Pharmacol; 1992 Jan; 225(1):37-41. PubMed ID: 1311687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.
    Smith RL; Canton H; Barrett RJ; Sanders-Bush E
    Pharmacol Biochem Behav; 1998 Nov; 61(3):323-30. PubMed ID: 9768567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activities of novel aryloxyalkylimidazolines on rat 5-HT2A and 5-HT2C receptors.
    Siegel BW; Freedman J; Vaal MJ; Baron BM
    Eur J Pharmacol; 1996 Feb; 296(3):307-18. PubMed ID: 8904083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes.
    Dalton GL; Lee MD; Kennett GA; Dourish CT; Clifton PG
    Neuropharmacology; 2004 Apr; 46(5):663-71. PubMed ID: 14996544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
    Willins DL; Meltzer HY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pindolol pretreatment blocks stimulation by meta-chlorophenylpiperazine of prolactin but not cortisol secretion in normal men.
    Meltzer HY; Maes M
    Psychiatry Res; 1995 Sep; 58(2):89-98. PubMed ID: 8570772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the behavioural effects of 5-HT2A and 5-HT2C receptor agonists in the pigeon.
    Wolff MC; Leander JD
    Behav Pharmacol; 2000 Aug; 11(5):355-64. PubMed ID: 11103887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of agonists, partial agonists, and antagonists on the regulation of 5-hydroxytryptamine2 receptors in P11 cells.
    Ferry RC; Unsworth CD; Molinoff PB
    Mol Pharmacol; 1993 May; 43(5):726-33. PubMed ID: 8388988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.